Recombinant IgE (Tanezumab Biosimilar) 抗体
Our Local Distributor
北京 101111
Quick Overview for Recombinant IgE (Tanezumab Biosimilar) 抗体 (ABIN7795148)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
-
-
Expression System
- Mammalian cells
-
原理
- Tanezumab Biosimilar, Human NGF Monoclonal Antibody
-
产品特性
- What is tanezumab biosimilar research grade? Tanezumab is a humanized IgG2-kappa monoclonal antibody against nerve growth factor (NGF) as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. Tanezumab selectively targets, binds to, and inhibits NGF. Tanezumab acts in the periphery in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse or dependence. Tanezumab biosimilar uses the same protein sequences as the therapeutic antibody tanezumab.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human NGF
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IgE (Tanezumab Biosimilar)
-
别名
- Tanezumab Biosimilar
-
物质类
- Biosimilar
抗原
-